Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Manson G, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Regny C, Bouabdallah K, Chauchet A, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Dercle L, Brice P, Houot R; Lymphoma Study Association (LYSA). Manson G, et al. Among authors: stamatoullas a. Br J Haematol. 2022 Jul;198(1):203-206. doi: 10.1111/bjh.18198. Epub 2022 Apr 21. Br J Haematol. 2022. PMID: 35445392 Free article. No abstract available.
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, Chaury MP, Braun T, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies (GFM). Natarajan-Amé S, et al. Among authors: stamatoullas a. Br J Haematol. 2012 Jul;158(2):232-237. doi: 10.1111/j.1365-2141.2012.09153.x. Epub 2012 May 10. Br J Haematol. 2012. PMID: 22571447 Free article. Clinical Trial.
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases.
Aussedat G, Traverse-Glehen A, Stamatoullas A, Molina T, Safar V, Laurent C, Michot JM, Hirsch P, Nicolas-Virelizier E, Lamure S, Regny C, Picquenot JM, Ledoux-Pilon A, Tas P, Chassagne-Clément C, Manson G, Lemal R, Fontaine J, Le Cann M, Salles G, Ghesquières H, Copie-Bergman C, Sarkozy C. Aussedat G, et al. Among authors: stamatoullas a. Br J Haematol. 2020 Apr;189(2):244-256. doi: 10.1111/bjh.16331. Epub 2020 Feb 6. Br J Haematol. 2020. PMID: 32030731 Free article.
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.
Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R; Lymphoma Study Association. Manson G, et al. Among authors: stamatoullas a. Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3. Blood. 2018. PMID: 29724901 Free article. No abstract available.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M. Casasnovas RO, et al. Among authors: stamatoullas a. Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15. Lancet Oncol. 2019. PMID: 30658935 Clinical Trial.
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.
Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P. Drevon L, et al. Among authors: stamatoullas a. Br J Haematol. 2018 Sep;182(6):843-850. doi: 10.1111/bjh.15490. Epub 2018 Jul 13. Br J Haematol. 2018. PMID: 30004110 Free article.
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. Díez-Campelo M, et al. Among authors: stamatoullas a. Br J Haematol. 2018 May;181(3):350-359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2. Br J Haematol. 2018. PMID: 29611196 Free article. Clinical Trial.
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Garnier G, Regny C, Bouabdallah K, Moles-Moreau MP, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Chauchet A, Damotte D, Dercle L, Brice P, Houot R; LYSA. Manson G, et al. Among authors: stamatoullas a. Eur J Cancer. 2019 Jul;115:47-56. doi: 10.1016/j.ejca.2019.04.006. Epub 2019 May 10. Eur J Cancer. 2019. PMID: 31082693
154 results